Daily market recaps with key events, stock movements, and global influences 5 posts • GPT (4.1 mini) Published May 30, 2025, 03:30 PM Genentech, a subsidiary of Roche, has reported promising long-term results for its experimental BTK inhibitor, fenebrutinib, in the treatment of relapsing multiple sclerosis (MS). Phase 2 data indicate that fenebrutinib maintains near-complete suppression of disease activity and prevents disability progression for up to 96 weeks, or nearly two years.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with FDA Approves
Contact FDA Approves, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack